PEI

Can Pancreatic Insufficiency Be Misdiagnosed as IBS? The Enzyme Deficiency Nobody Tests For

April 25, 20269 min readBy GLP1Gut Team
PEIpancreatic exocrine insufficiencyIBSmisdiagnosisfecal elastase

📋TL;DR: Pancreatic exocrine insufficiency is routinely misdiagnosed as IBS because fecal elastase testing is not part of the standard IBS workup. Mild PEI produces bloating, diarrhea, and gas that look identical to IBS-D. Steatorrhea is not always visually obvious in mild cases. Post-cholecystectomy patients, elderly populations, and people with a history of pancreatitis or heavy alcohol use are at highest risk for PEI being missed and labeled as IBS.

What We Know

  • Fecal elastase-1 testing is not included in Rome IV diagnostic criteria for IBS or in most standard IBS workup protocols (Lacy et al. 2016).
  • Mild PEI (fecal elastase 100-200 mcg/g) can produce symptoms identical to IBS-D without classic steatorrhea (Leeds et al. 2010).
  • Post-cholecystectomy patients have higher rates of fat malabsorption and may develop secondary PEI that presents as chronic diarrhea (Arafat et al. 2018).
  • Elderly patients experience age-related decline in pancreatic enzyme output, with subclinical PEI potentially contributing to unexplained GI symptoms (Rothenbacher et al. 2005).
  • A study by Leeds et al. (2010) found that 6.1% of patients meeting IBS criteria had fecal elastase values below 200 mcg/g, consistent with PEI.

What We Don't Know

  • How many patients currently diagnosed with IBS-D would test positive for PEI if fecal elastase were routinely ordered.
  • Whether treating mild PEI (fecal elastase 100-200 mcg/g) with PERT produces symptom improvement comparable to treating severe PEI.
  • The natural history of mild PEI in IBS patients: does it progress, remain stable, or sometimes resolve.
  • Whether combining fecal elastase testing with fecal fat quantification improves diagnostic accuracy for borderline cases.
  • The optimal approach for diagnosing PEI in patients with watery diarrhea, where dilute stool can produce falsely low elastase values.

Fecal elastase-1 is a simple stool test. It costs less than most blood panels. It requires no preparation, no fasting, and no dietary changes. It can identify whether your pancreas is producing enough digestive enzymes. And it is almost never ordered as part of an IBS workup. This is the core of why pancreatic exocrine insufficiency gets misdiagnosed as IBS. The Rome IV criteria used to diagnose IBS are symptom-based. They evaluate pain, stool frequency, and stool form. They do not evaluate pancreatic function. A patient whose pancreas produces insufficient lipase to digest dietary fat will develop bloating, gas, loose stools, and abdominal discomfort. These symptoms meet IBS-D criteria. The IBS label gets applied, and the enzyme deficiency goes undetected.

Why does this misdiagnosis happen?

The misdiagnosis occurs at the level of the diagnostic algorithm. The standard IBS workup includes a symptom assessment against Rome IV criteria, basic blood work (CBC, CRP, celiac serology, thyroid function), and sometimes a colonoscopy. These tests appropriately screen for celiac disease, inflammatory bowel disease, thyroid dysfunction, and colorectal pathology. They do not screen for pancreatic enzyme deficiency. Fecal elastase is not on the list. The rationale has historically been that PEI is associated with obvious pancreatic disease (pancreatitis, cystic fibrosis) and that patients without known pancreatic conditions are unlikely to have it. This assumption is wrong for a meaningful percentage of patients.

The Leeds et al. (2010) study tested fecal elastase in patients who met Rome criteria for IBS and found that 6.1% had values below 200 mcg/g, consistent with PEI. These patients had no prior diagnosis of pancreatic disease. Their symptoms were indistinguishable from other IBS patients based on clinical presentation. The only way to identify them was to test for the enzyme deficiency directly. Without the test, they would have remained in the IBS category indefinitely.

Why mild PEI looks like IBS-D

Classic PEI with severe enzyme deficiency produces obvious steatorrhea: stools that are pale, oily, bulky, and unmistakably different from normal. This presentation is hard to miss. But mild to moderate PEI is more subtle. The pancreas may retain enough function to digest most dietary fat but not all of it. The result is a partial malabsorption that produces looser stools, increased gas from bacterial fermentation of undigested fat in the colon, bloating, and mild abdominal discomfort. These symptoms are not dramatic enough to trigger suspicion of a pancreatic problem.

Patients with mild PEI often describe their stools as loose, frequent, and sometimes urgent. They may not notice that stools are fattier than normal, especially if they have been living with the pattern for months or years. They may attribute the smell to diet rather than malabsorption. From the patient's perspective, it feels like IBS. From the clinician's perspective, it looks like IBS. The distinction requires a test that is not being ordered.

Who is most at risk for this misdiagnosis?

Several patient populations are disproportionately likely to have PEI misclassified as IBS. Recognizing these risk factors can prompt the fecal elastase test that would identify the real problem.

  • Post-cholecystectomy patients. Gallbladder removal alters bile acid dynamics and can unmask or contribute to fat malabsorption. Chronic diarrhea after cholecystectomy is common, affecting 10-20% of patients. While bile acid diarrhea accounts for many of these cases, a subset have concurrent PEI. These patients are often diagnosed with post-cholecystectomy syndrome or IBS-D without pancreatic function testing.
  • Elderly patients. Pancreatic enzyme output declines with age. Subclinical PEI is more common in people over 65 and can present as vague GI symptoms attributed to aging, dietary changes, or IBS. Elderly patients with new-onset diarrhea and bloating should have fecal elastase checked, particularly if they are also losing weight.
  • Patients with a history of heavy alcohol use. Alcohol is the leading cause of chronic pancreatitis in Western populations, and chronic pancreatitis is the most common cause of PEI. Even patients without a formal diagnosis of chronic pancreatitis can have subclinical pancreatic damage from long-term alcohol use that reduces enzyme output enough to cause symptoms.
  • Patients with type 1 or type 2 diabetes. Diabetes, particularly type 1, is associated with PEI at rates higher than the general population. Autonomic neuropathy affecting the pancreas and shared autoimmune mechanisms are proposed explanations. Diabetic patients with chronic diarrhea labeled as IBS should be tested.
  • Patients with celiac disease. Celiac disease can impair cholecystokinin (CCK) release from damaged duodenal mucosa, reducing the signal that triggers pancreatic enzyme secretion. PEI can coexist with celiac disease and may not resolve with gluten-free diet alone if pancreatic function is independently compromised.

â„šī¸Steatorrhea becomes clinically apparent when fecal fat exceeds about 7 grams per day, which typically requires loss of more than 90% of pancreatic lipase output. Mild PEI with 50-80% enzyme loss can cause significant symptoms without producing stools that look obviously fatty. This is why relying on stool appearance to screen for PEI misses mild cases.

What to ask your doctor

If you suspect that your IBS-D might be related to pancreatic enzyme deficiency, these questions can help advance the conversation with your provider.

  • "I have been diagnosed with IBS-D but my symptoms are not improving with standard treatments. Can we check a fecal elastase-1 level to rule out pancreatic exocrine insufficiency?" This is a direct, evidence-based request for a simple test.
  • "I had my gallbladder removed and my diarrhea started afterward. Has pancreatic insufficiency been considered?" This connects a known risk factor to the symptom timeline.
  • "My stools seem to be oilier than they should be, and they float frequently. Could this be steatorrhea from fat malabsorption?" Describing specific stool characteristics gives your doctor clinical data beyond generic IBS symptoms.
  • "I have noticed unexplained weight loss along with my diarrhea. Should we test for malabsorption?" Weight loss in the context of chronic diarrhea is a red flag that shifts suspicion away from IBS toward organic causes like PEI.
  • "My vitamin D levels have been low despite supplementation. Could poor fat absorption from PEI be the reason?" Persistent vitamin D deficiency in a patient with diarrhea is a meaningful clinical clue for fat malabsorption.

What happens after the correct diagnosis?

When PEI is identified, the treatment is targeted and effective. Pancreatic enzyme replacement therapy (PERT) provides the lipase, amylase, and protease that the pancreas is not producing in adequate amounts. Patients take enzyme capsules with every meal and snack. Dosing starts at 40,000-50,000 lipase units per meal and 20,000-25,000 per snack, with adjustments based on symptom response and stool quality. PERT resolves steatorrhea and reduces bloating, gas, and diarrhea in the majority of patients. Fat-soluble vitamin levels are monitored, and supplementation is added as needed.

For many patients, the shift from years of ineffective IBS management to targeted enzyme replacement produces rapid, noticeable improvement. Stool quality normalizes. Bloating decreases. Weight stabilizes. The response to PERT itself serves as further confirmation that PEI, not IBS, was driving the symptoms.

Frequently Asked Questions

How common is PEI in people diagnosed with IBS?

A study by Leeds et al. (2010) found that 6.1% of patients meeting IBS criteria had fecal elastase levels below 200 mcg/g. This is likely an underestimate because the study used a single fecal elastase cutoff and mild PEI with borderline values may have been missed. The true prevalence in community IBS populations is unknown because routine testing is not performed.

Can I have PEI if I have never had pancreatitis?

Yes. While chronic pancreatitis is the most common cause of PEI, the condition can develop from pancreatic surgery, cystic fibrosis, celiac disease, diabetes, age-related atrophy, and in some cases without an identifiable cause. Not having a pancreatic disease history does not rule out PEI.

Why does my doctor not test for PEI routinely?

Fecal elastase is not included in standard IBS diagnostic guidelines. The Rome IV criteria focus on symptom patterns and exclude conditions like celiac disease and IBD, but PEI is not on the standard exclusion list. Many physicians are not aware of the overlap between mild PEI and IBS-D, particularly in patients without obvious pancreatic disease.

Can watery diarrhea affect the fecal elastase test result?

Yes. Very watery stool can dilute fecal elastase concentrations, potentially producing a falsely low result. To minimize this, the test should ideally be performed on a formed or semi-formed stool sample. If your stools are consistently watery, discuss this with your provider, as repeat testing or additional evaluation may be needed.

Is PEI the same as exocrine pancreatic insufficiency?

Yes, they are the same condition. PEI (pancreatic exocrine insufficiency) and EPI (exocrine pancreatic insufficiency) are interchangeable terms. Both refer to inadequate pancreatic enzyme production for normal fat digestion. Different medical sources may use either abbreviation.

âš ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Key Takeaways

  1. 1PEI is misdiagnosed as IBS because fecal elastase testing is not part of the standard IBS workup.
  2. 2Mild PEI does not always produce obvious steatorrhea. Stools may look similar to IBS-D stools.
  3. 3Post-cholecystectomy patients, elderly individuals, and people with any history of pancreatic disease are at higher risk for undiagnosed PEI.
  4. 4A single stool sample for fecal elastase-1 can identify PEI. The test is simple, inexpensive, and widely available.
  5. 5If you have IBS-D that is not responding to standard treatments, ask your doctor about fecal elastase testing.

Sources & References

  1. 1.The role of pancreatic exocrine insufficiency in patients with irritable bowel syndrome - Leeds JS et al., European Journal of Gastroenterology and Hepatology (2010)
  2. 2.Bowel Disorders (Rome IV criteria for IBS) - Lacy et al., Gastroenterology (2016)
  3. 3.Diarrhea and fat malabsorption following cholecystectomy: evaluation and management - Arafat M et al., Alimentary Pharmacology and Therapeutics (2018)
  4. 4.Prevalence and determinants of exocrine pancreatic insufficiency among older adults - Rothenbacher D et al., Scandinavian Journal of Gastroenterology (2005)
  5. 5.Clinical and pathophysiological consequences of the diagnosis of pancreatic exocrine insufficiency - Dominguez-Munoz JE, Pancreatology (2011)
  6. 6.Clinical and laboratory features of pancreatic exocrine insufficiency - Lindkvist B, World Journal of Gastroenterology (2013)
  7. 7.Exocrine Pancreatic Insufficiency - Cleveland Clinic Staff, Cleveland Clinic (2024)

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare professional before making changes to your diet, medications, or health regimen. GLP1Gut is a tracking tool, not a medical device.

Figure Out What's Actually Triggering You

An AI-powered meal and symptom tracker that connects what you eat to how you feel, built specifically for people on GLP-1 medications experiencing digestive side effects.